|
Azoospermia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Ala499Val (C>T) and Lys939Gln (A>C) polymorphism of XPC gene were genotyped by polymerase chain reaction-restriction fragment length polymorphism in three groups of infertile men (172 patients of azoospermia, 25 patients of severe oligozoospermia, 55 patients of oligozoospermia) and 228 fertile men.
|
18067564 |
2009 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive.
|
23918308 |
2014 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We investigated three polymorphisms of the XPC gene (PAT, Ala499Val and Lys939Gln) in 600 subjects with bladder cancer and in 609 healthy controls by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a Chinese Han population.
|
22505326 |
2012 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
In this work, we have conducted a case-control study in order to assess the effect of tobacco and three genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer development in Tunisia.
|
21426550 |
2011 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
A significant association between Ala499Val polymorphism and bladder cancer was observed (OR = 1.78, CI = 1.19-2.66, p = 0.005); however, Lys939Gln was unrelated (OR = 0.97, CI = 0.65-1.45, P = 0.89).
|
27246180 |
2016 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C-->T), PAT (-/+) and Lys939Gln (A-->C), with the risk of bladder cancer.
|
17052994 |
2007 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Using logistic regression adjusting for smoking, occupational and family history, neither the heterozygote nor the homozygote variants of these polymorphisms were associated with increased bladder cancer risk (adjusted odds ratio [95% confidence interval] for heterozygote 0.82 [0.63-1.07], 0.82 [0.63-1.08] and 0.83 [0.63-1.08] for PolyAT, IVS11-6 and Lys939Gln, respectively and homozygote variant, 0.98 [0.68-1.42], 0.99 [0.69-1.43] and 1.01 [0.70-1.46]).
|
15886698 |
2005 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We examined the associations between bladder cancer and 7 polymorphisms from 5 genes involved in the maintenance of genetic stability (MMR: MLH1-93G>A; BER: XRCC1--77T>C and Arg399Gln; NER:XPC Lys939Gln and PAT +/-; DSBR:ATM G5557A and XRCC7 G6721T) in 302 incident bladder cancer cases and 311 hospital controls.
|
22927776 |
2012 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52).
|
19924443 |
2010 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
We evaluated the association of two common non-synonymous polymorphisms in XPC (Ala499Val and Lys939Gln) with breast cancer risk in the Long Island Breast Cancer Study Project (LIBCSP), a population-based case-control study.
|
18053706 |
2008 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The current data suggested that XPC Ala499Val and Lys939Gln polymorphisms may contribute to the identification of patients with increased risk for BC.
|
22519360 |
2012 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Using data/samples collected from the first 752 Caucasians and 141 African-Americans in an ongoing case-control study, we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M.
|
18701435 |
2008 |
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Polymorphisms in Lys939Gln XPC gene may diminish DNA repair capacity, eventually increasing the risk of carcinogenesis.
|
26604426 |
2015 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this work, we have conducted a case-control study in order to assess the effect of tobacco and three genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer development in Tunisia.
|
21426550 |
2011 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Meta-analyses corroborated the above results, showing strong association of Ala499Val (OR = 1.54, CI = 1.21-1.97, p = 0.001) but not that of Lys939Gln (OR = 1.13, CI = 0.95-1.34, p = 0.171) with urinary bladder cancer risk.
|
27246180 |
2016 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive.
|
23918308 |
2014 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using logistic regression adjusting for smoking, occupational and family history, neither the heterozygote nor the homozygote variants of these polymorphisms were associated with increased bladder cancer risk (adjusted odds ratio [95% confidence interval] for heterozygote 0.82 [0.63-1.07], 0.82 [0.63-1.08] and 0.83 [0.63-1.08] for PolyAT, IVS11-6 and Lys939Gln, respectively and homozygote variant, 0.98 [0.68-1.42], 0.99 [0.69-1.43] and 1.01 [0.70-1.46]).
|
15886698 |
2005 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis suggested that the XPC Lys939Gln polymorphism contributed to the risk of urinary bladder cancer.
|
23819639 |
2013 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C-->T), PAT (-/+) and Lys939Gln (A-->C), with the risk of bladder cancer.
|
17052994 |
2007 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52).
|
19924443 |
2010 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest an association between the XPC genotypes of the A499V, K939Q and PAT polymorphisms and urinary-bladder cancer.
|
20887739 |
2010 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated three polymorphisms of the XPC gene (PAT, Ala499Val and Lys939Gln) in 600 subjects with bladder cancer and in 609 healthy controls by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a Chinese Han population.
|
22505326 |
2012 |